

## Tasigna - (150mg, 200mg Capsule oral)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | NILOTINIB HYDROCHLORIDE MONOHYDRATE  | <b>Innovator</b>            | Novartis            |
| <b>Dosage</b>                | 150mg, 200mg Capsule oral  | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | More Than 5  | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | Less Than 5  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Tasigna (nilotinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Tasigna is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Tasigna - (50 mg; Capsule)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | NILOTINIB HYDROCHLORIDE MONOHYDRATE   | <b>Innovator</b>            | Novartis            |
| <b>Dosage</b>                | 50 mg; Capsule  | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5   | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | More Than 5   | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | Less Than 5   | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.